{"organizations": [], "uuid": "f8ad035d42b189806dbc5ce40fc88bd1ce64201d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biogen-and-neurimmune-announce-opt/brief-biogen-and-neurimmune-announce-option-exercise-for-alzheimers-disease-investigational-treatment-aducanumab-idUSFWN1S807A", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T15:23:00.000+03:00", "replies_count": 0, "uuid": "f8ad035d42b189806dbc5ce40fc88bd1ce64201d"}, "author": "", "url": "https://www.reuters.com/article/brief-biogen-and-neurimmune-announce-opt/brief-biogen-and-neurimmune-announce-option-exercise-for-alzheimers-disease-investigational-treatment-aducanumab-idUSFWN1S807A", "ord_in_thread": 0, "title": "BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "biogen", "sentiment": "none"}, {"name": "biogen inc", "sentiment": "none"}, {"name": "alzheimer", "sentiment": "none"}, {"name": "biogen inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "disease investigational treatment aducanumab reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 12:23 PM / Updated 25 minutes ago BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab Reuters Staff\nMay 1 (Reuters) - Biogen Inc:\n* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMERâ€™S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB\n* BIOGEN - WILL MAKE A ONE-TIME $50 MILLION PAYMENT TO NEURIMMUNE FOR 5% REDUCTION IN ORIGINAL ROYALTY RATES ON POTENTIAL COMMERCIAL SALES OF ADUCANUMAB\n* BIOGEN INC - HAS EXERCISED ITS OPTION TO FURTHER REDUCE PREVIOUSLY NEGOTIATED ROYALTY RATES PAYABLE ON POTENTIAL FUTURE SALES OF ADUCANUMAB Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T15:23:00.000+03:00", "crawled": "2018-05-01T15:55:13.075+03:00", "highlightTitle": ""}